Two down two to go
When it comes to the earnings announcement from Lilly last week only one thing matters and one thing only – from the earnings release “Lilly announces today its U.S. submission of tirzepatide in type 2 diabetes using a priority review voucher”. Anyone who has reviewed the extensive data portfolio complied for tirzepatide understands why expectations are sky high and why Lilly isn’t screwing around using a priority review voucher. Lilly may not know jack when it comes to diabetes devices but when it comes to this drug, they know they have a mega blockbuster.
The submission will . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.